ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2018年09月03日 16時00分
Source:
Eisai
エーザイ、中心循環系血管内塞栓促進用補綴材「ディーシー ビーズ」使用目的又は効果の一部削除の承認について
東京, 2018年09月03日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫)は、このたび、日本において、中心循環系血管内塞栓促進用補綴材「ディーシー ビーズ(R)」(高度管理医療機器、以下 本品)について、使用目的又は効果の一部削除が承認され、使用目的又は効果が「多血性腫瘍(子宮筋腫を除く)を有する患者に対する動脈塞栓療法」となりましたことをお知らせします。
今回の使用目的又は効果の一部削除の承認は、実臨床上、本品は「子宮筋腫」及び「動静脈奇形」に対して使用されないことから、関連学会に確認の上、当局と相談し、当該適応に係る使用目的又は効果の取り下げの一部変更承認申請を行っていたことに基づくものです。
当社は、本使用目的又は効果の一部削除に際し、医療関係者の皆様への適切な情報提供に努めてまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2018/news201876.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Mazda Production and Sales Results for December 2024 and for January through December 2024
Jan 30, 2025 16:44 JST
Lexus Announces Global Sales Results for 2024
Jan 30, 2025 15:52 JST
MHI Thermal Systems Receives 2024 Agency for Natural Resources and Energy Commissioner's Award from ECCJ for TEJ35AM Electric-Driven Transport Refrigeration Unit Integrated with Isuzu's ELF EV
Jan 30, 2025 14:13 JST
Mitsubishi Shipbuilding Receives Order for an Offshore Patrol Vessel from the Indonesian Maritime Security Agency
Jan 30, 2025 12:35 JST
Fujitsu and Asepeyo collaborate to modernise the management of occupational benefits and contingencies
Jan 30, 2025 11:56 JST
Suzuki, Daihatsu, and Toyota Decide on the Release Schedule for Mini-Commercial Van Electric Vehicles
Jan 30, 2025 10:56 JST
A Quantum Leap into Uplisting: Spectral Capital and the Next Generation of Computing
Jan 29, 2025 22:47 JST
NEC combines video analysis technology with generative AI to generate advice for improving work quality
Jan 29, 2025 10:08 JST
Japan's Telecommunications Carriers Strengthen Disaster Response by Conducting Joint Training for Shared Refueling Stations
Jan 28, 2025 17:39 JST
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 28, 2025 09:46 JST
Ogier's milestone Monte win crowns TOYOTA GAZOO Racing one-two
Jan 27, 2025 17:24 JST
Anime Tokyo Station: Let's Enjoy together!! History of Anime Series "OSHI NO KO"
Jan 27, 2025 13:00 JST
hootfolio, Inc., a Provider of Causal Analysis Technology, Launches Business Development
Jan 27, 2025 12:01 JST
Sustainable Shared Transport and Fujitsu launch open platform for joint transportation and delivery in Japan, enhancing logistics efficiency across industries
Jan 27, 2025 10:53 JST
DOCOMO to Exhibit at MWC Barcelona 2025, World's Largest Connectivity Exhibition
Jan 24, 2025 17:39 JST
Hitachi Launches Food Quality Visualization Solution with Time-Temperature Sensing Ink
Jan 24, 2025 12:40 JST
Mitsubishi Heavy Industries Aero Engines and Rolls-Royce Celebrate 20 Years of Collaboration
Jan 24, 2025 10:38 JST
World's First Successful Transmission of Huge Volume Mission Data Using 1.5 micron Optical Inter-Satellite Communication
Jan 24, 2025 09:19 JST
TANAKA PRECIOUS METAL TECHNOLOGIES Develops AgSn TLP Sheet, a Sheet-type Bonding Material for Power Semiconductors
Jan 23, 2025 11:00 JST
MHI Receives Order for 3 New Series Trainsets (12 Cars) for Seibu Railway's Yamaguchi Line
Jan 22, 2025 17:27 JST
More Latest Release >>
Related Release
FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
1/28/2025 9:46:00 AM JST
Eisai Listed as a Global 100 Most Sustainable Corporation for The Ninth Time Highest Ranked Global Pharmaceutical Company
1/22/2025 5:18:00 PM JST
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
1/15/2025 10:03:00 AM JST
Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer's Disease
1/7/2025 9:14:00 AM JST
Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
12/23/2024 5:22:00 PM JST
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
12/11/2024 2:45:00 PM JST
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
12/5/2024 11:22:00 AM JST
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
11/28/2024 4:26:00 PM JST
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
11/26/2024 3:50:00 PM JST
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
11/20/2024 11:51:00 AM JST
More Press release >>